Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes

作     者：Jung Wan Choe Hyo Jung Kim Jae Seon Kim Jaehyung Cha Moon Kyung Joo Beom Jae Lee Jong-Jae Park Young-Tae Bak 

作者机构：Department of Internal MedicineKorea University College of MedicineSeoul 08308Korea Department of BiostatisticsKorea University Medical CenterSeoul 08308Korea 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2018年第17卷第3期

页      面：263-268页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100214[医学-肿瘤学] 10[医学] 

基　　金：Korea University Medical Center 

主　　题：Diabetes mellitus Pancreatic neoplasms Early detection of cancer Carbohydrate antigen 19-9 Bilirubin 

摘      要：Background： Generally, carbohydrate antigen 19–9 （CA 19–9） is not useful for screening pancreatic cancerin the asymptomatic general population. This study aimed to evaluate the utility of CA 19–9 level as a screening indicator of pancreatic cancer in asymptomatic patients with new-onset diabetes.